UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

Congratulations to Anita Moser, Head of U.S. Neurology Assets and Optimization, and Erica Puntel, U.S. Neurology and Global Digital Business Transformation Communications Lead, for their recognition as Healthcare Businesswomen's Association (HBA) Rising Stars for 2021.